Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index; 19 of the 36 sources its claims cite were checked for support.
Abstract
BACKGROUND: Diabetes mellitus is associated with an increased risk of cardiovascular events. Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear. METHODS: We randomly assigned adults who had diabetes but no evident cardiovascular disease to receive aspirin at a dose of 100 mg daily or matching placebo. The primary efficacy outcome was the first serious vascular event (i.e., myocardial infarction, stroke or transient ischemic attack, or death from any vascular cause, excluding any confirmed intracranial hemorrhage). The primary safety outcome was the first major bleeding event (i.e., intracranial hemorrhage, sight-threatening bleeding event in the eye, gastrointestinal bleeding, or other serious bleeding). Secondary outcomes included gastrointestinal tract cancer. RESULTS: A total of 15,480 participants underwent randomization. During a mean follow-up of 7.4 years, serious vascular events occurred in a significantly lower percentage of participants in the aspirin group than in the placebo group (658 participants [8.5%] vs. 743 [9.6%]; rate ratio, 0.88; 95% confidence interval [CI], 0.79 to 0.97; P=0.01). In contrast, major bleeding events occurred in 314 participants (4.1%) in the aspirin group, as compared with 245 (3.2%) in the placebo group (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), with most of the excess being gastrointestinal bleeding and other extracranial bleeding. There was no significant difference between the aspirin group and the placebo group in the incidence of gastrointestinal tract cancer (157 participants [2.0%] and 158 [2.0%], respectively) or all cancers (897 [11.6%] and 887 [11.5%]); long-term follow-up for these outcomes is planned. CONCLUSIONS: Aspirin use prevented serious vascular events in persons who had diabetes and no evident cardiovascular disease at trial entry, but it also caused major bleeding events. The absolute benefits were largely counterbalanced by the bleeding hazard. (Funded by the British Heart Foundation and others; ASCEND Current Controlled Trials number, ISRCTN60635500 ; ClinicalTrials.gov number, NCT00135226 .).
Overview
CoChat Summary
TL;DR
In adults with diabetes and no evident cardiovascular disease, low-dose aspirin reduced serious vascular events but increased major bleeding, with absolute benefits largely counterbalanced by bleeding hazards. Aspirin did not reduce gastrointestinal or overall cancer incidence over a mean follow-up of 7.4 years.
Key findings
- Serious vascular events occurred in 658 aspirin-group participants (8.5%) vs. 743 placebo-group participants (9.6%) (rate ratio, 0.88; 95% CI, 0.79 to 0.97; P=0.01).
- Major bleeding occurred in 314 aspirin-group participants (4.1%) vs. 245 placebo-group participants (3.2%) (rate ratio, 1.29; 95% CI, 1.09 to 1.52; P=0.003), mostly gastrointestinal and other extracranial bleeding.
- No significant between-group difference was found for gastrointestinal tract cancer (157 [2.0%] vs. 158 [2.0%]) or any cancer (897 [11.6%] vs. 887 [11.5%]).
- Absolute effects: 91 patients would need to be treated to avoid a serious vascular event over 7.4 years, and 112 to cause a major bleeding event.
Methods
- Randomized trial of 15,480 adults with diabetes but no evident cardiovascular disease, assigned to aspirin 100 mg daily or matching placebo; factorial assignment also included n-3 fatty acids or placebo.
- Primary efficacy outcome was first serious vascular event (myocardial infarction, stroke or transient ischemic attack, or vascular death, excluding confirmed intracranial hemorrhage); primary safety outcome was first major bleeding event.
- Intention-to-treat time-to-event analyses used log-rank methods; mean follow-up was 7.4 years, with estimated mean adherence 70% in each group.
Limitations
- Stated: analyses for cancer had limited statistical power to detect hypothesized effects, and longer-term follow-up is planned or being continued.
- Stated: intention-to-treat analyses underestimate the effects of actual aspirin use because adherence was incomplete; secondary and exploratory outcomes were not adjusted for multiple comparisons, so confidence intervals should not be used to infer definitive subgroup or secondary effects.
- Evident from the text: participants were predominantly white (96.5%), had type 2 diabetes (94.1%), were recruited in the United Kingdom, and were well treated with cardioprotective therapies (e.g., 75.6% statin use in the aspirin group), which may limit generalizability.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 Valid · 1 Not valid · 4 Not checked · 53 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report fewer serious vascular events with aspirin in both primary and secondary prevention trials. The Abstract’s Interpretation explicitly describes a reduction in occlusive events, while noting that bleeding risk must be weighed against this benefit in primary prevention. (LLM, conf=0.94)
- Supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. source
The Antiplatelet agents/anticoagulants recommendations (page not provided) recommend aspirin for patients with coronary artery disease and state that it reduces saphenous vein graft closure after bypass surgery. This supports the attributed claim that aspirin reduces occlusive vascular events in the guideline’s secondary-prevention setting; the separate statement about first events in diabetes is not part of the quoted claim. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“On average, however, the approximate 50% higher risk of bleeding with aspirin use than with control counterbalanced much of the benefit in these low-risk patients.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report about a 50% increase in major gastrointestinal and other extracranial bleeding with aspirin in primary-prevention trials (RR 1.54). The Discussion says aspirin’s absolute benefits are much smaller in primary than in secondary prevention and that its benefits and bleeding hazards can be approximately balanced, supporting the claim about low-risk patients. (LLM, conf=0.93)
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Only approximately 4% of participants in those trials had diabetes, and the lower relative risk among them was similar to that observed among participants without diabetes (as was also observed in the context of secondary prevention).”
What the sources say
- Partly supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) says that, in the primary-prevention trials, the proportional reduction in serious vascular events did not differ significantly by history of diabetes. This supports the main comparison, but the passages do not establish the citing sentence’s approximately 4% figure or its diabetes-specific comparison in secondary prevention. (LLM, conf=0.82)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The 2009 Antithrombotic Trialists' Collaboration meta-analysis involving 95,000 patients in six primary prevention trials showed that assignment to aspirin use led to a 12% (95% confidence interval [CI], 6 to 18) lower risk of serious vascular events than control. 1”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
Split into 2 atoms — 2 confirmed, 0 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a causen = 95,000- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Aspirin use reduces the risk of occlusive vascular events but increases the risk of bleeding; the balance of benefits and hazards for the prevention of first cardiovascular events in patients with diabetes is unclear.”
What the sources say
- Supportedcites [1] 1. Antithrombotic Trialists' Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-60. source
The Results report that aspirin increased major gastrointestinal and other extracranial bleeds in primary prevention trials, with a significant excess of major bleeds also observed in secondary prevention trials. This supports the attributed claim that aspirin increases bleeding risk. (LLM, conf=0.94)
- Partly supportedcites [2] 2. Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011; 124: 2458-73. sourceExperimental — accuracy not yet measured
The Antiplatelet agents/anticoagulants recommendations (page unavailable) state that warfarin used with aspirin and/or clopidogrel is associated with increased bleeding risk. The References also list a study of bleeding complications at different aspirin doses, but the guideline passage does not establish the unqualified claim that aspirin use alone increases bleeding risk. (LLM, conf=0.81)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
37 more claims · 6 with their cited sources checked
Create a free account to see all 72 claims and every source verdict.
- It may state two separate claims as one. 16
- Probably not a substantial claim. 19
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The benefit of ASA in the ASCEND trial was observed on top of statins (75% of patients) and/or anti-hypertensive (∼60% of patients) drugs.292”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [292]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people > 70 years of age (with or without diabetes), the balance appears to have greater risk than bene fi t (144,146).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [144]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“however, the ASCEND trial found benefit of low-dose aspirin in those in this weight range, which would not validate this suggested hypothesis (179).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For people >70 years of age (with or without diabetes), the balance appears to have greater risk than benefit (179,181).”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“There were no significant differences by sex, weight, or duration of diabetes or other baseline factors, including ASCVD risk score.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [179]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
The Emerging Risk Factors Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)60484-9 · Cited by 5,125
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Smith, S. C., Benjamin, E. J., Bonow, R. O., Braun, L. T., Creager, M. A., Franklin, B. A., Gibbons, R. J., Grundy, S. M., Hiratzka, L. F., Jones, D. W., et al. (2011) · Circulation · doi:10.1161/cir.0b013e318235eb4d · Cited by 1,759
Rothwell, P. M., Fowkes, F. G. R., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62110-1 · Cited by 1,497
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Rothwell, P. M., Wilson, M., Price, J. F., Belch, J. F., Meade, T. W., & Mehta, Z. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60209-8 · Cited by 984
Cited by
Items 901–1,000 of 1,171
Kombinierte antithrombotische Therapiestrategien in der Kardiologie
Moser, M. (2019) · Kardiologie up2date · doi:10.1055/a-0720-1003
Farmakoterapia po Kongresie ESC 2018 w Monachium - na które pytania znamy już odpowiedź?
Pawliczak, F., & Kasprzak, J. D. (2019) · Folia Cardiologica · doi:10.5603/fc.2018.0126
Selección de lo mejor del año 2018 en riesgo vascular y rehabilitación cardiaca
Frías, P. T., Ruíz, R. C., Duque, J. A. A., Senén, A. B., Olmo, M. R. F., & Jiménez, M. A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.01.007 · Cited by 2
Was gibt es Neues zum Aspirin? Stellenwert in der Primärprophylaxe von Herz-Kreislauf-Erkrankungen
Hoffmeister, H. M. (2019) · Der Klinikarzt · doi:10.1055/a-0861-9497
Singh, A. (2019) · Heart India · doi:10.4103/heartindia.heartindia_10_19
Aspirin for primary prevention: The changing paradigms!
Pradhan, A. K., Gupta, V., & Vishwakarma, P. (2019) · Heart India · doi:10.4103/heartindia.heartindia_5_19
Ten things you should know about type 2 diabetes – part 2
Morris, D. (2019) · Independent Nurse · doi:10.12968/indn.2019.4.22
The Year in Vascular Anesthesia: Selected Highlights From 2018
Valentine, E. A., Zhou, E., Gold, A. K., & Ochroch, E. A. (2019) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2019.04.011
Top studies relevant to primary care from 2018: From PEER.
Perry, D., Moe, S., Korownyk, C. S., Lindblad, A. J., Kolber, M. R., Thomas, B., Ton, J., Garrison, S., & Allan, G. M. (2019) · PubMed Central
Principales études en rapport avec les soins primaires en 2018: Par le groupe PEER
Perry, D., Moe, S., Korownyk, C. S., Lindblad, A. J., Kolber, M. R., Thomas, B., Ton, J., Garrison, S., & Allan, G. M. (2019) · PubMed Central
Devuyst, S., Gigase, A., Spapen, J., et al. (2019) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt.2019.04.10
Frolova, E. V. (2019) · Russian Family Doctor · doi:10.17816/rfd2019127-34
Cardiovascular primary prevention – directed approach for individual features
Mano, T. B., Rosa, S. A., Rio, P., Timóteo, A. T., & Ferreira, R. C. (2019) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2019.07.022
Diabetes Update 2019: Was ist für die Praxis Neues zu beachten
Scherbaum, W. A. (2019) · Der Diabetologe · doi:10.1007/s11428-019-0485-5
Acetylsalicylic acid for primary prevention of cardiovascular events.
Fritsch, P., & Kolber, M. R. (2019) · PubMed
Neues beim Schlaganfall unter besonderer Berücksichtigung älterer Patienten
Diener, H., Gerloff, C. P., Grond, M., Häusler, K. G., Heuschmann, P., Huttner, H. B., Röther, J., Schwab, S., Sprügel, M. I., Thomalla, G., et al. (2019) · Neurologie up2date · doi:10.1055/a-0829-8928
Editorial commentary: MicroRNAs as effectors and indicators of aspirin therapeutic potential
Pierce, J. B., & Feinberg, M. W. (2019) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2019.09.002
Aspirin for primary prevention of cardiovaascular events: what are the evidances?
Yenny, Y. (2019) · Universa Medicina · doi:10.18051/univmed.2019.v38.145-146
Prevenzione primaria della malattia cardiovascolare: c’è bisogno di un’aspirina?
Floccari, F., Marrocco, F., Rivera, R. F., & Lullo, L. D. (2019) · Giornale di Clinica Nefrologica e Dialisi · doi:10.1177/0394936219875389
Neues beim Schlaganfall unter besonderer Berücksichtigung älterer Patienten
Diener, H., Gerloff, C. P., Grond, M., Häusler, K. G., Heuschmann, P., Huttner, H. B., Röther, J., Schwab, S., Sprügel, M. I., Thomalla, G., et al. (2019) · Geriatrie up2date · doi:10.1055/a-0966-1716
Zur Prävention von Herz-Kreislauf-Erkrankungen nicht geeignet
Medizin, S. (2019) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-019-0191-2
Jain, M., & Childers, C. (2019) · Annals of Internal Medicine · doi:10.7326/acpj201911190-055
Patient with diabetes after acute coronary event. How to improve forecast?
Барбараш, О. Л. (2019) · Medical alphabet · doi:10.33667/2078-5631-2019-1-3(378)-6-11
A kardiovaszkuláris kockázat csökkentése 1-es típusú diabetes mellitusban, felnőttkorban
Hosszúfalusi, N., & Kempler, M. (2019) · Diabetologia Hungarica · doi:10.24121/dh.2019.12
La DAPT chez le patient diabétique coronarien
Dillinger, J., & Henry, P. (2019) · Archives of Cardiovascular Diseases Supplements · doi:10.1016/s1878-6480(19)30959-0
Osugi, Y., Ino, T., Kobayashi, D., Iwata, M., & Asai, K. (2019) · BMC Geriatrics · doi:10.1186/s12877-019-1394-6
Selección de lo mejor del año 2019 en cardiología clínica
Cosín-Sales, J., Cortés, C. O., Llergo, J. T., Huelmos, A. I., Barrios, V., Escobar, C., López‐Fernández, T., & Martínez, J. M. G. (2020) · REC CardioClinics · doi:10.1016/j.rccl.2019.10.012
Mudra, A. K. (2020) · Physician Assistant Clinics · doi:10.1016/j.cpha.2019.11.009
Schlaganfall – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
Uphaus, T., & Gröschel, K. (2021) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-62426-5_43
Thrombozytenhemmung bei Diabetes mellitus Typ 2: Neue Strategien und aktuelle Studienergebnisse
Said, S. A., Bode, C., & Dürschmied, D. (2020) · Der Klinikarzt · doi:10.1055/a-1122-4022
Dörr, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-38647-4_4
PURL: Aspirin, Yes, for at-risk elderly-but what about the healthy elderly?
Piggott, C., & Lyon, C. (2020) · PubMed
Yokoyama, K. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.92379
Larina, V. N., Gaydina, T. A., Mkrtychev, D. S., Кузнецова, В. А., & Snezhko, Z. (2020) · Kardiologiia · doi:10.18087/cardio.2020.3.n928
Aydın, V., Akıcı, A., Sakarya, S., Akman, M., & Fak, A. S. (2020) · TURKISH JOURNAL OF MEDICAL SCIENCES · doi:10.3906/sag-1907-144
Bosetti, C., Santucci, C., Gallus, S., & Vecchia, C. L. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.025
Consenso AURORA: risco cardiovascular na pessoa com diabetes mellitus tipo 2
de Família, M., Maricoto, T., Antunes, J. P., de Família, M., Pereira, M. R., de Família, M., Corte-Real, S., de Família, M., Taveira‐Gomes, T., de Família, M., et al. (2020) · Revista Portuguesa de Clínica Geral · doi:10.32385/rpmgf.v36i3.12744 · Cited by 3
Critical Appraisal of the ASCEND Trial
Ozaki, A. F., & Jackevicius, C. A. (2019) · Journal of Contemporary Pharmacy Practice · doi:10.37901/jcphp18-00031
Kontroverze - aspirin po PCI?Aspirin po PCI: proč podávat
Vojáček, J. (2020) · Intervenční a akutní kardiologie · doi:10.36290/kar.2020.041
Author response: The dimension of preventable stroke in a large representative patient cohort
Boehme, C., Toell, T., Knoflach, M., et al. (2020) · Neurology · doi:10.1212/wnl.0000000000010592
Gender Differences and Evidence-Based Medicine: Navigating the Wide Knowledge Gap
Gamad, N., Patil, A., & Kakkar, A. K. (2020) · American Journal of Therapeutics · doi:10.1097/mjt.0000000000001263
Enikuomehin, A. C., Kolawole, B. A., Ikem, R. T., & Soyoye, B. (2015) · Endocrine Abstracts · doi:10.1530/endoabs.38.p264
Aboul‐Hassan, S. S., Stankowski, T., Marczak, J., Pęksa, M., Nawotka, M., Stanisławski, R., Moskal, Ł., Lipowski, A., Sá, M. P., & Cichoń, R. (2020) · Brazilian Journal of Cardiovascular Surgery · doi:10.21470/1678-9741-2020-0313
Aspirin for Primary Prevention—Unveiling a Historical Truth and Choosing the Right Patient
Rao, B. H. (2020) · Indian Journal of Clinical Cardiology · doi:10.1177/2632463620976273
Cardiodiabetology: Reducing Risks to Optimize Cardiovascular Disease Outcomes
Wong, N. D., & Handelsman, Y. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_12 · Cited by 1
Kam, W., & Husseini, N. E. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56279-3_24
Nicolas, J., Goel, R., Claessen, B. E. P. M., & Mehran, R. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-820536-5.00008-2
Anticoagulation and Antiplatelet Guidelines
Olson, S. R., & Bannow, B. S. (2021) · Springer eBooks · doi:10.1007/978-3-030-53626-8_13
Koczo, A., Goodwin, A. M., McNeil, M., & Jones, S. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-50695-7_22
Prevention of Cardiovascular Disease
Sharma, G. V., Minhas, A., & Michos, E. D. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819369-3.00013-7
Herz-Kreislauf-Sterblichkeit wird nicht reduziert
Diener, H. (2020) · InFo Neurologie + Psychiatrie · doi:10.1007/s15005-019-1242-4
on behalf of the CSCA Investigators, Xu, Y., Gu, H., Li, Z., Xiong, Y., Zhou, Q. G., Liu, L., Zhao, X., Wang, Y., Meng, X., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-7902
Ma, H., Gu, Q., Niu, H., Li, X., & Wang, R. (2021) · doi:10.22541/au.162247344.43377091/v1
Declining Rates of ICD Therapies in a Secondary Prevention Population
Bender, A. B., & Boyle, N. G. (2021) · JACC. Clinical electrophysiology · doi:10.1016/j.jacep.2020.11.028 · Cited by 1
Diabetes mellitus, platelet function and acetylsalicylic acid
Gendeleka, G. F., & Gendeleka, A. N. (2021) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.17.3.2021.232660
Improving outcomes for older people with diabetes
Morris, D. (2021) · Practice Nursing · doi:10.12968/pnur.2021.32.7.270
Luna, J. A. G., López‐Medina, E., Maldonado-Vargas, N. D., & Smith, A. D. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.17036.1
Gualberto, F. C. M., Valentin, A. A. D. S., de Oliveira, D. R., et al. (2021) · Research Society and Development · doi:10.33448/rsd-v10i9.17417
Kim, K., DeMets, D. L., Martinez, L. C., Biglione, B., Gitin, A., Gaziano, J. M., Pfeffer, M. A., Hennekens, C. H., & Wood, S. K. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3897697
Matsuzaki, S., Miller, H., Takiuchi, T., Klar, M., & Matsuo, K. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1973427 · Cited by 1
Cardiometabolic Risk Reduction: A Review of Clinical Guidelines and the Role of SGLT-2 Inhibitors
Reid (2021) · The Journal of Family Practice · doi:10.12788/jfp.0216
Use of SGLT-2 Inhibitors in Patients with Chronic Kidney Disease
Mottl (2021) · The Journal of Family Practice · doi:10.12788/jfp.0225 · Cited by 3
Improving Shingles Vaccination Rates in Family Medicine
Luther (2021) · The Journal of Family Practice · doi:10.12788/jfp.0218
The Challenge: Finding the Most Appropriate Statin and Dose for Each Patient
Lillo (2021) · The Journal of Family Practice · doi:10.12788/jfp.0224
Cavallari, I., Filippis, A. D., Nobile, E., Veneziano, F. A., Melfi, R., Nusca, A., Ussia, G. P., & Grigioni, F. (2021) · L Endocrinologo · doi:10.1007/s40619-021-00954-w
Conclusion de la séance dédiée aux médicaments de prévention cardiovasculaire
Bouvenot, G. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.09.006
Rationality and safety of acetylsalicylic acid therapy in centenarians
Alimova, E. R., & Eruslanova, K. A. (2021) · Russian Journal of Geriatric Medicine · doi:10.37586/2686-8636-3-2021-371-375
Should my older adult patients take aspirin for primary prevention of cardiovascular disease?
Zimbroff, R. M., Ayers, G. T., & Koncilja, K. (2021) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.88a.21024
Picard, F. A., & Camus, M. (2021) · La Presse Médicale Formation · doi:10.1016/j.lpmfor.2021.10.011 · Cited by 2
Prather, C., Adams, E. N., Zentgraf, W., Puhl, J., & Barnett, S. D. (2021) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2021.573
Sibon, I., & Liegey, J.-S. (2021) · Revue Neurologique · doi:10.1016/j.neurol.2021.07.021
Treatment Strategies in Patients with Diabetes Mellitus and Ischemic Heart Disease
Mahowald, M. K., Locker, C. L., Singh, M., & Frye, R. L. (2021) · Wiley eBooks · doi:10.1002/9781119603207.ch19
Adjusted Morbidity Groups and Intracerebral Haemorrhage: A Retrospective Primary Care Cohort Study
Lorman-Carbó, B., Clua‐Espuny, J. L., Múria-Subirats, E., Ballesta-Ors, J., González-Henares, M. A., Pallejà-Millán, M., & Martín‐Luján, F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph182413320
Wang, T., Wu, J., Dong, W., Wang, M., Zhong, X., Zhang, W., Dai, L., Xie, Y., Liu, Y., He, X., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-176723/v1
Macrovascular disease in diabetes
Rudy Bilous MD, F., Donnelly, R., & Iskandar Idris DM, F. (2021) · Wiley eBooks · doi:10.1002/9781118976074.ch20
Acetylsalicylsäure: Heutiger Stellenwert in der antithrombotischen Therapie
Zeymer, U. (2019) · Deutsches Ärzteblatt · doi:10.3238/perskardio.2019.04.12.01
Hanna, E. B. (2022) · Wiley eBooks · doi:10.1002/9781119832737.ch24
Geriatric Pharmacology Case Series: Direct Oral Anticoagulants for Older People With Cancer
Tsu, L. V., Nguyen, C., & Ramos, R. (2022) · The Senior Care Pharmacist · doi:10.4140/tcp.n.2022.49
The 5th Annual Heart in Diabetes Conference (part 2)
Bloomgarden, Z. T. (2022) · Journal of Diabetes · doi:10.1111/1753-0407.13251
Kulecki, M., Naskręt, D., Kamiński, M., Kasprzak, D., Lachowski, P., Klause, D., Kozłowska, M., Uruska, A. A., Zozulińska‐Ziółkiewicz, D., & Flotyńska, J. (2021) · Research Square · doi:10.21203/rs.3.rs-144455/v1
Appropriate Use of Aspirin in the Primary and Secondary Prevention: Results From the ASSOS StudyPreprint
Çelik, O., Çil, C., Başaran, Ö., Demirci, E., Tanık, V. O., Altuntaş, E., Sancar, K. M., Örsçelik, Ö., Yetim, M., Bekar, L., et al. (2022) · doi:10.22541/au.164864769.91331063/v1
Aspirin resistance: causes, clinical significance, correction
Gendeleka, G. F., & Gendeleka, A. N. (2022) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.18.2.2022.1157
Greener, M. (2018) · Independent Nurse · doi:10.12968/indn.2018.11.18
Schlaganfall – Prävalenz, Bedeutung und Implikationen für die Prävention und Gesundheitsförderung
Uphaus, T., & Gröschel, K. (2019) · Springer Reference Pflege, Therapie, Gesundheit · doi:10.1007/978-3-662-55793-8_43-1
Evaluación y manejo del riesgo cardiovascular residual en el paciente con diabetes
Orna, J. A. G., Toro, J. J. O., & Miranda, C. M. P. (2020) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2020.06.003 · Cited by 1
Selección de lo mejor del año 2019 en riesgo vascular y rehabilitación cardiaca
Arrarte, V., Campuzano, R., Carro, A., Castro, A., Dalmau, R., Sandín, M., Velasco, E., & Valle, A. (2019) · REC CardioClinics · doi:10.1016/j.rccl.2019.10.015 · Cited by 1
Four recommendations for aspirin use to reduce ASCVD risk: An evidence-based review
Castelli, G., & Wilson, S. A. (2022) · Evidence-Based Practice · doi:10.1097/ebp.0000000000001451
López‐Candales, A., & Norgard, N. B. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2082716
Prevention of Major Amputation secondary to Diabetes-related Foot Disease
Hayes, J. M. (2022) · Cronfa (Swansea University) · doi:10.23889/suthesis.60123
4 Clinical applications of aspirin
Schrör, K. (2022) · De Gruyter eBooks · doi:10.1515/9783110746419-004
Ethnic Factors in the Assessment of Cardiovascular Risk for Primary Prevention
Bhatia, H. S., Xu, I., Taub, P. R., & Wilkinson, M. J. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_11
European Guidelines for Risk Assessment in the Primary Prevention of Cardiovascular Disease
Cawley, C., & McEvoy, J. W. (2022) · Contemporary cardiology · doi:10.1007/978-3-030-98824-1_3 · Cited by 2
Meta-Analysis of Aspirin for Primary Prevention of Stroke
Zheng, P., Mao, Y., Yan, X., Ding, J., & Ou, Y. (2022) · Yangtze Medicine · doi:10.4236/ym.2022.62004
Kirchner, J. T. (2021) · Oxford University Press eBooks · doi:10.1093/med/9780197576595.003.0045
Balletshofer, B. M., Böckler, D., die, D. G. G., Diener, H., Heckenkamp, J., Ito, W. D., Katoh, M., Lawall, H., die, D. G. A., Malyar, N. M., et al. (2022) · Die Diabetologie · doi:10.1007/s11428-022-00904-6
Cieri‐Hutcherson, N. E., Lomakina, A., & Chilbert, M. R. (2022) · Pharmacy · doi:10.3390/pharmacy10050105
Metadata
- Authors
- The ASCEND Study Collaborative Group
- Affiliations
- MRC Population Health Research Unit (GB)
- Corresponding author
- The ASCEND Study Collaborative Group
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-10-18
- Volume
- 379
- Issue
- 16
- Pages
- 1529-1539
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899755710
- Cited by
- 1,200
- References
- 23
- Citations by year
- 2026: 66 · 2025: 105 · 2024: 123 · 2023: 117 · 2022: 170 · 2021: 176 · 2020: 193 · 2019: 214 · 2018: 33
- FWCI
- 116.42
- Type
- journal article
- Language
- en
- Open access
- green
- ora.ox.ac.uk
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Oxford University Research Archive (ORA) (University of Oxford) (submittedVersion)
- Funders
- Mylan EPD
- Solvay Pharmaceuticals
- Bayer Schering
- British Heart Foundation (SP/03/02, SP/08/010/25939, SP/14/13/31114)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- diabetes mellitus, aspirin, primary prevention, cardiovascular events, major bleeding, gastrointestinal bleeding, intracranial hemorrhage, myocardial infarction, stroke, cancer incidence, benefits and risks, ASCEND trial, occlusive vascular disease, antiplatelet therapy, cardiovascular risk reduction, gastrointestinal cancer, cancer mortality
- MeSH terms
- Aged, Aged, 80 and over, Aspirin, Cardiovascular Diseases, Diabetes Mellitus, Female, Follow-Up Studies, Hemorrhage, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Primary Prevention, Risk Factors, Poisson Distribution, Diabetes Complications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-16, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-16 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.